Why the study?
Does atrial overdrive pacing reduce the need for cardioversion and antiarrhythmic drugs in adult patients with congenital heart disease and recurrent intra-atrial reentrant tachycardia?
Does atrial overdrive pacing reduce the need for cardioversion and antiarrhythmic drugs in adult patients with congenital heart disease and recurrent intra-atrial reentrant tachycardia?
Atrial overdrive pacing significantly reduces the need for cardioversion and antiarrhythmic drugs in patients with congenital heart disease and recurrent intra-atrial reentrant tachycardia.
May support atrial overdrive pacing in adult CHD with recurrent IART; hypothesis-generating and requires prospective validation.
BACKGROUND: Intra-atrial reentrant tachycardia (IART) is a common arrhythmia in adult patients with palliated congenital heart disease (CHD). Traditional treatment methods such as antiarrhythmic drugs (AADs) or radiofrequency ablation are often unsuccessful or cause side effects. These patients often require frequent cardioversion and anticoagulation. The purpose of this study is to evaluate the success of overdrive atrial pacing for the suppression of IART in CHD. METHODS: Single center, investigational review board approved, retrospective review of nine patients with CHD and documented, recurrent IART. Patients served as their own historical controls for this study. Phase I was defined as the period 2 years prior to atrial pacing intervention, and Phase II was defined as > or =13 months with atrial pacing; enabled or implanted rate responsive or dynamic overdrive A pacing. During Phase II, the patients' rhythm was monitored by either symptom reporting, ECG, Holter monitoring or pacer diagnostics every 2 months. RESULTS: Cardioversion post A pacing decreased: from 25 to 3, P < .003, patients requiring cardioversions 9 to 1, P < .001, no. AADs 18 to 7, P < .02. CONCLUSIONS: Overdrive atrial pacing, > or =70 ppm, is a viable treatment option to suppress recurrent IART. With the suppression of IART, the need for cardioversion, and AAD can be significantly reduced.
No takes yet. Share an insight, caveat, or question.
Snyder et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: